Jiangzhong pharmaceutical: it is estimated that the total operating revenue in the first quarter of 2022 will be about 890 million yuan, with a year-on-year increase of about 30%

China’s E-bike Brands Going Global: A Review of 26 Leading Players

With the global e-bike market continuing to expand, Chinese e-bike companies are gradually shifting from being a manufacturing powerhouse to becoming a meaningful force in global competition. This article reviews a group of Chinese e-bike players and examines their overseas positioning and market entry paths—looking at how Chinese brands are securing a foothold in the next wave of globalization.

Politburo Meeting Sets Tone for "15th Five-Year Plan" Start, Addressing "Involuted" Competition and Implementing "AI Plus" Initiative

On April 28, the Political Bureau of the CPC Central Committee (中共中央政治局) held a meeting to analyze the current economic situation. The meeting noted that China's economy saw a strong start in the first quarter (GDP grew 5.0% year-on-year), with major indicators exceeding expectations. As the first Politburo meeting focused on economic work following the start of the "15th Five-Year Plan" (十五五) cycle, it released policy signals characterized by a high sense of urgency.

Ask EqualOcean — China Intelligence, On Demand

Your direct line to what's really happening in China.

Unpacking China | Key Chinese Firms to Watch This Week （19/04/2026-25/04/2026）

Amid fast-paced changes that fill the business community with excitement, angst and trepidation, EqualOcean will publish a series of roundup articles to document the major events related to Chinese companies going global every week.

CTTQ, Ampsourcebio Ink Agreement on Cure for NASH, T2DM

There are more than 95 plus major players and more than 90 plus nonalcoholic steatohepatitis (NASH) pipeline therapies, but none of them has been approved for marketing. Who would survive the competition in the blue-ocean market for NASH?